1. Introduction {#s0005}
===============

Nasopharyngeal carcinoma (NPC) is an uncommon malignancy with distinct geographic and ethnic characteristics. GLOBOCAN estimates that approximately 86,700 new cases of NPC have been reported, leading to an estimated 50,800 deaths in 2012 ([@bb0185]). NPC occurs frequently, with an incidence rate of 15 to 50 per 100,000 people annually in Southeast Asia. However, the incidence rate is not higher than 1 per 100,000 people in Western countries ([@bb0240], [@bb0230]). Unfortunately, distant metastasis is a main cause of death for NPC patients, which often has an unfavorable prognosis ([@bb0030], [@bb0035], [@bb0115]). Although computed tomography (CT) and magnetic resonance imaging (MRI) are effective, they cannot accurately provide a prognosis for NPC or predict the effectiveness of biological therapeutic targets ([@bb0110], [@bb0070]). Thus, a novel, noninvasive low-cost biomarker for early detection of NPC is of great importance to clinical practice.

DNA methylation, which is a common mechanism in epigenetic alterations, may be correlated with NPC ([@bb0085], [@bb0145]). Promoter methylation of tumor suppressor genes (TSGs), such as calcium channel voltage-dependent alpha 2/delta subunit 3 (*CACNA2D3*) and cadherin 4 (*CDH4*), may play a crucial role in NPC development and progression ([@bb0200], [@bb0055]). Localized in human chromosomal region 3p21.3, the RAS association domain family protein 1A (*RASSF1A*) is an important TSG involved in multiple biological functions, including cell cycle regulation, microtubule stabilization, and apoptosis ([@bb0010], [@bb0005], [@bb0015]). In NPC, *RASSF1A* gene expression is often blocked due to promoter methylation ([@bb0195], [@bb0065], [@bb0125]). *RASSF1A* promoter methylation can be detected in tissue, brushing and blood samples of patients with NPC ([@bb0150], [@bb0220], [@bb0080]).

However, there are some inconsistencies in reports on the level of the *RASSF1A* promoter methylation in NPC. For example, Chang et al. reported that the rate of *RASSF1A* promoter methylation in NPC patients was different in tissue (66.7%), blood (3.3%), and brushing samples (33.3%) ([@bb0025]). Yang et al. reported that the *RASSF1A* promoter region was frequently methylated in 68.8% of brushing samples from NPC patients ([@bb0220]). Therefore, the aim of this study was to assess the relationship between *RASSF1A* promoter methylation and NPC risk in tissue, brushing, and blood samples. Moreover, we analyzed the correlation of *RASSF1A* promoter methylation with clinicopathological features of patients with NPC. Finally, we determined the diagnostic utility of *RASSF1A* promoter methylation as a noninvasive biomarker in samples of tissue, brushings, and blood.

2. Materials and Methods {#s0010}
========================

2.1. Search Strategy {#s0015}
--------------------

We conducted a systematic search of online electronic databases (PubMed, Embase, EBSCO, Web of Science, Scopus and the Cochrane Library) to identify eligible literature published prior to January 11, 2017. The following combination of key words and search terms were used to identify studies: 'nasopharyngeal cancer or nasopharyngeal neoplasm or nasopharyngeal carcinoma or nasopharyngeal tumor or NPC', 'RASSF1A or RAS association domain family protein 1A', 'methylation or methylated or epigene\*'. We also carefully checked the references of eligible articles to identify other potential studies. This study was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria ([@bb0140]) ([Table S1](#ec0005){ref-type="supplementary-material"}).

2.2. Inclusion Criteria {#s0020}
-----------------------

Studies were included in this meta-analysis if they fulfilled the following selection criteria: 1) patients were diagnosed with primary NPC based on histopathological examination of samples, including tissue, brushing, and blood; 2) articles were published in English; 3) there was sufficient information on the level of *RASSF1A* promoter methylation in NPC and non-tumor samples; 4) there was sufficient data for estimating the relationship between *RASSF1A* promoter methylation and the clinicopathological characteristics of patients with NPC. If multiple papers were published using overlapping sample data, we only included the most appropriate article with the most detailed information.

2.3. Data Extraction {#s0025}
--------------------

Two authors independently scanned and abstracted the following information from available studies: surname of first author, year of publication, country, population by race, sample types, number of cases and non-tumor controls, methodology for the detection of methylation, rate of *RASSF1A* promoter methylation, expression status of the *RASSF1A* gene, and clinicopathological parameters, such as age (\> 50 years vs. ≤ 50 years), sex (male vs. female), clinical stage (stage 3--4 vs. stage 1--2), lymph node status (positive vs. negative status), distant metastasis (yes vs. no), and T classification (T3--4 vs. T1--2). Any inconsistent data or information was resolved by a discussion including all authors.

2.4. Statistical Analysis {#s0030}
-------------------------

Pooled data in this meta-analysis were analyzed using Stata software, version 12.0 (STATA Corp., College Station, TX, USA). The strength of the correlation between *RASSF1A* promoter methylation and NPC was estimated by the combined odds ratios (ORs) with 95% confidence intervals (95% CIs). The pooled ORs and corresponding 95% CIs were also used to analyze the relationship between *RASSF1A* promoter methylation and the clinicopathological features of NPC patients, including age, sex, clinical stage, lymph node status, distant metastasis, and T classification. Potential heterogeneity among studies was detected using Cochran\'s Q test ([@bb0040]). The random-effects model was applied when Q-test P values were \< 0.1, indicating obvious heterogeneity. A fixed-effect model was applied to the data when the P values were \> 0.1, indicating no evidence of heterogeneity ([@bb0075], [@bb0045]). Meta-regression analyses were performed to assess the sources of heterogeneity. Sensitivity analyses were conducted to determine whether removing individual studies with substantial heterogeneity changed the overall OR ([@bb0105]). Egger\'s test was used to evaluate potential publication bias for results with more than nine studies ([@bb0060]). Based on the bivariate analysis, we generated the combined sensitivity, specificity, and the summary receiver operator characteristic (SROC) curve (AUC) to evaluate the diagnostic capacity of *RASSF1A* promoter methylation in tissue, blood, and brushing samples from NPC patients in the meta-analysis ([@bb0165], [@bb0090]).

3. Results {#s0035}
==========

3.1. Study Characteristics {#s0040}
--------------------------

[Fig. 1](#f0005){ref-type="fig"} lists a detailed procedure for our literature search in a range of online electronic databases. After a careful screen based on the inclusion criteria described above, we identified 16 studies, including 926 patients with NPC and 495 non-tumor controls, with sufficient data in the final meta-analysis ([@bb0150], [@bb0220], [@bb0175], [@bb0020], [@bb0080], [@bb0195], [@bb0065], [@bb0235], [@bb0155], [@bb0160], [@bb0205], [@bb0025], [@bb0210], [@bb0180], [@bb0100], [@bb0125]). Of the 16 eligible studies, 11 investigated the correlation between *RASSF1A* promoter methylation and NPC in tumor versus non-tumor tissues ([@bb0150], [@bb0020], [@bb0195], [@bb0065], [@bb0235], [@bb0160], [@bb0025], [@bb0210], [@bb0180], [@bb0100], [@bb0125]). Four studies determined the relationship between *RASSF1A* promoter methylation and NPC in tumor versus non-tumor blood samples ([@bb0220], [@bb0175], [@bb0205], [@bb0025]). Four studies analyzed the association between *RASSF1A* promoter methylation and NPC in tumor versus non-tumor brushing samples ([@bb0220], [@bb0080], [@bb0025], [@bb0180]). Eight studies involving 502 NPC patients assessed the relationship between *RASSF1A* promoter methylation and the clinicopathological characteristics of patients with NPC ([@bb0220], [@bb0175], [@bb0195], [@bb0065], [@bb0235], [@bb0155], [@bb0205], [@bb0180]). [Table 1](#t0005){ref-type="table"} and [Table S2](#ec0010){ref-type="supplementary-material"} present the general characteristics of the studies included in the meta-analysis.

3.2. Association Between *RASSF1A* Promoter Methylation and NPC in Cancer vs. Control Samples {#s0045}
---------------------------------------------------------------------------------------------

[Fig. 2](#f0010){ref-type="fig"} shows the significant relationship between *RASSF1A* promoter methylation and NPC risk in cancerous samples compared with control samples (tissue: OR = 29.81, 95% CI = 11.27--78.86, P \< 0.001; brushing: OR = 75.74, 95% CI = 20.70--277.10, P \< 0.001; blood: OR = 5.21, 95% CI = 1.50--18.04, P = 0.009). This comparison included 365 NPC and 179 non-tumor tissue samples, 207 NPC and 139 non-tumor brushing samples, and 331 NPC and 177 non-tumor blood samples.

3.3. Subgroup, Sensitivity and Meta-Regression Analyses in Tumor Versus Non-tumor Tissues {#s0050}
-----------------------------------------------------------------------------------------

Subgroup analysis was conducted by ethnicity (Asian and Caucasian populations), and the results showed that *RASSF1A* promoter methylation was closely correlated with NPC risk in both Asian and Caucasian populations (OR = 14.73, 95% CI = 7.33--29.60, P \< 0.001 and OR = 67.89, 95% CI = 15.41--299.10, P \< 0.001, respectively) ([Fig. 3](#f0015){ref-type="fig"}).

There was a slight heterogeneity in measurements comparing NPC and non-tumor tissues (P = 0.066 \< 0.1). A sensitivity analysis was carried out to estimate the influence of deleting an individual study on the overall result. When we removed the study by Zhou et al. ([@bb0235]) (control: adjacent tissue samples) and recalculated, the combined OR was 47.35 (95% CI = 20.08--111.66, P \< 0.001) and there was no significant heterogeneity (P = 0.971).

To explore sources of heterogeneity, we performed meta-regression analyses using race (Asian and Caucasian populations) and multiple control types (normal, non-tumor, and adjacent tissue samples) ([Table 2](#t0010){ref-type="table"}). The results demonstrated that ethnicity was not the source of the heterogeneity we observed (P \> 0.1). However, control type analysis revealed that the heterogeneity was from adjacent tissue samples (P = 0.012), which is consistent with the sensitivity analysis.

3.4. Association Between *RASSF1A* Promoter Methylation and Age or Sex of NPC {#s0055}
-----------------------------------------------------------------------------

The results showed that the status of *RASSF1A* promoter methylation was not associated with age (133 NPC patients) and sex (471 NPC patients) in NPC (OR = 0.77, 95% CI = 0.36--1.64, P = 0.496 and OR = 1.42, 95% CI = 0.86--2.34, P = 0.168, respectively) ([Fig. 4](#f0020){ref-type="fig"}).

3.5. Association Between *RASSF1A* Promoter Methylation and Clinical Stage or Lymph Node Status of NPC {#s0060}
------------------------------------------------------------------------------------------------------

The analysis included data on the clinical stage of 403 patients with NPC and the lymph node status of 214 patients with NPC. The results showed that *RASSF1A* promoter methylation was associated with clinical stage and lymph node status (OR = 2.16, 95% CI = 1.26--3.70, P = 0.005 and OR = 3.96, 95% CI = 1.17--13.48, P = 0.027, respectively) ([Fig. 5](#f0025){ref-type="fig"}).

3.6. Association Between *RASSF1A* Promoter Methylation and Distant Metastasis or T Classification of NPC {#s0065}
---------------------------------------------------------------------------------------------------------

The analysis included data on of distant metastasis in 359 NPC patients and T classification in 252 NPC patients. The results showed that methylation of the *RASSF1A* promoter was associated with distant metastasis and T classification in NPC (OR = 6.16, 95% CI = 2.85--13.31, P \< 0.001 and OR = 2.04, 95% CI = 1.16--3.59, P = 0.014, respectively) ([Fig. 6](#f0030){ref-type="fig"}).

3.7. Publication Bias {#s0070}
---------------------

The analysis of publication bias was measured in tumor versus non-tumor tissue samples ([Fig. S1](#f0050){ref-type="graphic"}) and revealed obvious evidence of publication bias (P \< 0.001). After one study was removed ([@bb0235]), (control: adjacent tissue samples), the recalculated publication bias was significantly decreased (P = 0.674).

3.8. Diagnostic Utility of *RASSF1A* Promoter Methylation in Cancer vs. Controls {#s0075}
--------------------------------------------------------------------------------

To evaluate the diagnostic capacity of *RASSF1A* promoter methylation, we compared sample types (tissue, brushing, and blood) from NPC and control. Based on their identification as a source of heterogeneity, adjacent tissue samples were excluded from the analysis. The pooled sensitivity, specificity and AUC of *RASSF1A* promoter methylation in tissue samples were 0.72 (95% CI = 0.64--0.80), 0.99 (95% CI = 0.92--1.00), and 0.98 (95% CI = 0.96--0.99), respectively ([Fig. 7](#f0035){ref-type="fig"}). The overall sensitivity, specificity and AUC of the brushing samples were 0.56 (95% CI = 0.37--0.73), 1.00 (95% CI = 0.63--1.00), and 0.94 (95% CI = 0.91--0.95), respectively ([Fig. 8](#f0040){ref-type="fig"}). The combined sensitivity, specificity and AUC of the blood samples were 0.11 (95% CI = 0.05--0.25), 0.98 (95% CI = 0.93--1.00), and 0.97 (95% CI = 0.95--0.98), respectively ([Fig. 9](#f0045){ref-type="fig"}). The sensitivity of the tissue and brushing groups (tissue: 0.72 and brushing: 0.56) was higher compared with the blood group (a weak sensitivity = 0.11). These results suggest that testing for *RASSF1A* promoter methylation may provide a non-invasive method for diagnosing NPC in tissue and brushing samples.

4. Discussion {#s0080}
=============

Multiple factors are involved in NPC pathogenesis, including the Epstein-Barr virus, environmental, genetics and epigenetic components ([@bb0190], [@bb0130]). *RASSF1A* is a key TSG in various human cancers ([@bb0050]). DNA methylation of TSG promoters leads to dysfunction or loss of gene expression, including *RASSF1A*, which may play a key role in the development of NPC ([@bb0065], [@bb0095], [@bb0120]). Numerous studies with small populations have indicated that the frequency of *RASSF1A* promoter methylation is significantly increased in NPC tissue samples compared with non-tumor tissue samples ([@bb0150], [@bb0020], [@bb0195], [@bb0065]). Our results, comprised of 11 studies forming a large population, confirm that *RASSF1A* promoter methylation was notably more common in NPC compared with non-tumor tissues, which indicates that methylation of the *RASSF1A* promoter is closely linked to NPC tumorigenesis.

Subgroup analysis by ethnicity (Asian and Caucasian populations) on *RASSF1A* promoter methylation in NPC compared with non-tumor tissues showed that methylation was associated with an increased risk of NPC in both Asian and Caucasian populations. These results suggest that *RASSF1A*, with promoter methylation, may be a susceptibility gene for Asians and Caucasians with NPC. We found a slight heterogeneity (P = 0.066) and performed a sensitivity analysis to determine the stability of the pooled OR by omitting an individual study ([@bb0235]), control: adjacent tissue samples). The combined OR from the remaining studies was also significant and heterogeneity was dramatically reduced (P = 0.971). The main reason for bias in the current result may be contamination of tissue samples adjacent to the nasopharynx by NPC cells. Furthermore, the result of meta-regression analysis was consistent with the sensitivity analysis, suggesting that our analyses are stable and credible.

*RASSF1A* promoter methylation was not correlated with age in the four studies that analyzed it ([@bb0195], [@bb0235], [@bb0155], [@bb0180]). *RASSF1A* promoter methylation was not associated with sex in the eight studies that analyzed it ([@bb0220], [@bb0175], [@bb0195], [@bb0065], [@bb0235], [@bb0155], [@bb0205], [@bb0180]). Our results were consistent, showing no relationship between *RASSF1A* promoter methylation, age and sex of NPC patients. In a large population (189 NPC patients), Yang et al. ([@bb0220]) reported a significant relationship between *RASSF1A* promoter methylation and clinical stage, distant metastasis, and T classification. The remaining articles, which had small populations, reported no correlation between *RASSF1A* promoter methylation clinical stage ([@bb0175], [@bb0195], [@bb0235], [@bb0155], [@bb0205], [@bb0180]), distant metastasis ([@bb0195], [@bb0065], [@bb0155], [@bb0180]), and T classification ([@bb0155], [@bb0180]). There was a significant relationship between *RASSF1A* promoter methylation and lymph node status in 68 patients with NPC ([@bb0065]). However, the remaining papers (\< 42 NPC patients per study) showed no association between *RASSF1A* promoter methylation and lymph node status ([@bb0195], [@bb0155], [@bb0205], [@bb0180]). The current findings, based on multiple studies, reveal that *RASSF1A* promoter methylation was correlated with clinical stage, lymph node status, distant metastasis, and T classification. Furthermore, it was notably higher in advanced stage compared with early stage NPC patients, higher in lymph node positive- compared with lymph node negative patients, higher in patients with distant metastasis compared with patients without distant metastasis, and higher in patients with T3--4 classification compared with patients with T1--2 classification. These results suggest that *RASSF1A* promoter methylation plays an important role in the progression and metastasis of NPC. Thus, *RASSF1A* promoter methylation may be associated with a poor prognosis for patients with NPC and serve as a potential therapeutic drug target.

This study reveals a significant relationship between *RASSF1A* promoter methylation and NPC in tissue, brushing and blood samples, indicating that *RASSF1A* promoter methylation may be a noninvasive biomarker for NPC. Several studies have suggested that aberrant DNA methylation of cancer-specific genes (e.g., TSGs) in various types of human samples could be used for noninvasive cancer screening and diagnosis ([@bb0225], [@bb0215], [@bb0135], [@bb0170]). Therefore, we investigated whether *RASSF1A* promoter methylation can serve as a diagnostic biomarker for NPC. The pooled specificity and AUC of *RASSF1A* promoter methylation were very good in tissue, brushing and blood samples of patients with NPC vs. corresponding non-tumor samples (tissue: specificity = 0.99, AUC: 0.98; brushing: specificity = 1.00, AUC: 0.94; blood: specificity = 0.98, AUC: 0.97 \> 0.9). The combined sensitivity of *RASSF1A* promoter methylation was higher in the tissue and brushing groups (0.72, 95% CI = 0.64--0.80 and 0.56, 95% CI = 0.37--0.73, respectively) compared with the blood group, which had a bad value (0.11, 95% CI = 0.05--0.25). We also found that the sensitivity and specificity of *RASSF1A* promoter methylation were better in the tissue (91.2% and 100%, respectively) and brushing samples (75.5% and 97.9%, respectively). These findings suggest that *RASSF1A* promoter methylation is an effective noninvasive biomarker for the diagnosis of NPC in tissue and brushing samples. In the future, additional well-designed clinical studies with large populations will be necessary to validate the diagnostic potential of *RASSF1A* promoter methylation for NPC patients, particularly in brushing samples.

This study has several limitations. First, only papers published in English were included. Publications in languages other than English were excluded due to insufficient information, which may lead to selection bias. Second, this study involved largely Asians and Caucasians; other ethnic subgroups (e.g., Africans) were lacking. In addition, several of the studies were based on a small Caucasian population. In the future, additional studies with large Caucasian and African populations are necessary. Third, further prospective studies using quantitative detection methodologies (i.e., pyrosequencing, MethyLight, methylation-sensitive high resolution melting, etc.) are needed to confirm the role of *RASSF1A* promoter methylation as a biomarker for the diagnosis of NPC. Finally, the correlation between *RASSF1A* promoter methylation and the clinicopathological characteristics of NPC patients requires further validation because of the limited sample size.

5. Conclusions {#s0085}
==============

The findings from this study suggest that *RASSF1A* promoter methylation is more common in NPC than in non-tumor tissue, brushing, and blood samples. Furthermore, *RASSF1A* promoter methylation was higher in later stage than in early stage patients, higher in patients with lymph node metastasis than without, higher in patients with distant metastasis than those without, and higher in patients with T3--4 classification than in patients with T1--2 classification. In addition, *RASSF1A* promoter methylation may be a diagnostic biomarker in tissue and brushing samples that could be used for the clinical diagnosis of NPC. In the future, well-matched prospective studies are essential for determining the prognostic and diagnostic significance of *RASSF1A* promoter methylation in patients with NPC.
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###### 

Baseline characteristics of the eligible studies considered in this report.

Table 1

  First author   Country           Ethnicity    Age    Method       Stage   Sample     Control sample   Cancer   Control      Clinical features   Expression         
  -------------- ----------------- ------------ ------ ------------ ------- ---------- ---------------- -------- ------------ ------------------- ------------ ----- ------
  ([@bb0125])    China             Asians       NA     MSP          NA      Tissue     Normal           14       21 (66.7)    0                   6 (0.0)      NA    Loss
  ([@bb0100])    China             Asians       NA     MSP          NA      Tissue     Normal           24       29 (82.8)    0                   6 (0.0)      NA    NA
  ([@bb0180])    China             Asians       52.3   MSP          1--4    Brushing   Non-tumor        11       28 (39.3)    0                   12 (0.0)     Yes   NA
  ([@bb0180])    China             Asians       NA     MSP          1--4    Tissue     Non-tumor        8        16 (50.0)    0                   12 (0.0)     Yes   NA
  ([@bb0210])    China             Asians       NA     MSP          NA      Tissue     Normal           13       28 (46.4)    0                   5 (0.0)      NA    NA
  ([@bb0025])    China             Asians       49     MSP          1--4    Tissue     Normal           20       30 (66.7)    0                   6 (0.0)      NA    NA
  ([@bb0025])    China             Asians       49     MSP          1--4    Brushing   Normal           10       30 (33.3)    0                   37 (0.0)     NA    NA
  ([@bb0025])    China             Asians       49     MSP          1--4    Blood      Normal           1        30 (3.3)     1                   43 (2.3)     NA    NA
  ([@bb0205])    China             Asians       46     MethyLight   1--4    Blood      Normal           2        41 (4.9)     0                   43 (0.0)     Yes   NA
  ([@bb0160])    Singapore         Asians       NA     MSP          NA      Tissue     Normal           20       27 (74.1)    0                   20 (0.0)     NA    NA
  ([@bb0155])    China             Asians       NA     MSP          1--4    Tissue     NA               17       23 (73.9)    NA                  NA           Yes   NA
  ([@bb0235])    China             Asians       NA     MSP          1--4    Tissue     Adjacent         23       28 (82.1)    34                  56 (60.7)    Yes   NA
  ([@bb0235])    China             Asians       NA     MSP          1--4    Tissue     Non-tumor        23       28 (82.1)    0                   8 (0.0)      NA    NA
  ([@bb0065])    Tunisia           Caucasians   42     MSP          1--4    Tissue     Normal           62       68 (91.2)    0                   9 (0.0)      Yes   Loss
  ([@bb0195])    China             Asians       NA     MSP          1--4    Tissue     Normal           27       38 (71.1)    0                   14 (0.0)     Yes   Loss
  ([@bb0080])    The Netherlands   Caucasians   NA     MSP          1--4    Brushing   Non-tumor        40       53 (75.5)    1                   47 (2.1)     NA    NA
  ([@bb0020])    Tunisia           Caucasians   45     MSP          1--4    Tissue     Non-tumor        27       36 (75.0)    0                   19 (0.0)     NA    NA
  ([@bb0175])    China             Asians       50.2   MSP          2--4    Blood      Normal           7        40 (17.5)    2                   41 (4.9)     Yes   NA
  ([@bb0220])    China             Asians       NA     MS-HRM       NA      Brushing   Non-tumor        66       96 (68.8)    0                   43 (0.0)     NA    NA
  ([@bb0220])    China             Asians       NA     MS-HRM       1--4    Blood      Non-tumor        53       220 (24.1)   0                   50 (0.0)     Yes   NA
  ([@bb0150])    Sweden            Caucasians   NA     MSP          NA      Tissue     Non-tumor        29       44 (65.9)    1                   18 (5.6)     NA    NA

MSP: methylation-specific polymerase chain reaction; MS-HRM: methylation-sensitive high resolution melting; M: methylation; N: number of participants; NA: not applicable.

###### 

Meta-regression analysis in tumor versus non-tumor tissues.

Table 2

  Subgroup        Coefficient (95% CI)         t        P value
  --------------- ---------------------------- -------- ---------
  Race            1.308 (− 1.113, 3.728)       1.2      0.257
  Control types                                         0.012
  Normal          0.009 (− 1.998, 2.015)       0.01     0.993
  Adjacent        − 2.761 (− 4.756, − 0.767)   − 3.13   0.012

95% CI: 95% confidence interval.
